Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001562180-24-001995 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-02-29 | 2024-02-27 | AKBA | Hadas Nicole R. | SVP, CLO | S - Sale | $1.52 | -7,411 | 669.2K | -1% | -$11.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-27 | S | D | 7,411 | $1.52 | 669,233 | D | — | — | (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. |